Exploring the IKBKB Gene's Role in Psoriasis and Psoriatic Arthritis
IKBKB Gene Polymorphism (Single Nucleotide Polymorphism) (SNP) in Psoriatic and Psoriatic Arthritis Patients and Its Relation With Response to Systemic Biologic Therapy
This study is testing how changes in the IKBKB gene might affect the severity of psoriasis and psoriatic arthritis in people aged 16 to 60 who are being treated with Humira.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 50 (estimated) |
| Ages | 16 Years to 60 Years |
| Sex | All |
| Sponsor | South Valley University Academic / other |
| Drugs / interventions | adalimumab, certolizumab, infliximab, ustekinumab, secukinumab, ixekizumab, bimekizumab, brodalumab, guselkumab, tildrakizumab, risankizumab, mirikizumab, methotrexate |
| Locations | 1 site (Qinā) |
| Trial ID | NCT06729463 on ClinicalTrials.gov |
What this trial studies
This study investigates the genetic factors associated with psoriasis and psoriatic arthritis, focusing on the IKBKB gene polymorphism. It aims to understand the relationship between genetic variations and the severity of these conditions, which affect a significant portion of the population. Patients aged 16 to 60 with moderate to severe psoriasis will be treated with Humira, a medication known for its effectiveness in managing inflammatory diseases. The study seeks to identify potential genetic markers that could inform treatment strategies and improve patient outcomes.
Who should consider this trial
Good fit: Ideal candidates are patients aged 16 to 60 with clinically diagnosed moderate to severe psoriasis for at least 6 months.
Not a fit: Patients currently receiving immunosuppressive drugs or those with active infections or serious comorbidities may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more personalized treatment options for patients with psoriasis and psoriatic arthritis based on their genetic profiles.
How similar studies have performed: While genetic studies in psoriasis have been conducted, this specific focus on the IKBKB gene polymorphism is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients between the ages of 16 and 60 years proved having psoriasis diagnosed clinically for at least 6 months and who have a severity grade of moderate to severe, defined as a Psoriasis Area and Severity Index (PASI) score greater than 10, and involvement of greater than 10% of the body surface area (BSA) with or without psoriatic arthritis Exclusion Criteria: * Patient receiving immune suppressive drugs. * Patients having malignancy. * Pregnant or lactating female. * Patients having liver disease ( Hepatitis) * Patients having comorbid and/or uncontrolled renal, cardiac, vascular, and hepatic diseases or symptoms. * Active infection or human immunodeficiency virus (HIV) * Tuberculosis
Where this trial is running
Qinā
- South Valley Hospitals — Qinā, Egypt (Recruiting)
Study contacts
- Study coordinator: Fatma Abdel-Monem Mahmoud, Resident
- Email: abdomonem2014@yahoo.com
- Phone: +201005305240
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.